Science 37 Collaborates with AWS to Enable Faster, Patient-Friendly, Clinical Research
RESEARCH TRIANGLE PARK, N.C., April 20, 2023—Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research industry-leading Metasite™, today announced a multi-year relationship with Amazon Web Services (AWS) to scale and accelerate adoption of the Science 37 Metasite, which provides clinical trial sponsors the ability to securely engage with patients beyond traditional clinical trial sites.
Science 37 will become a partner in the AWS Partner Network (APN), which will help reach more customers and providers. Science 37 will continue to leverage the security and reliability of AWS, in addition to its analytics and machine learning (ML) services to help improve decision-making, support patient safety, and reduce the length of trial lifecycles.
“We are excited to join the AWS Partner Network where we expect to leverage the global scale, expertise, and security of AWS to reach more customers," said Michael Shipton, Chief Commercial Officer at Science 37. “We also see an opportunity to expand our network of partners to support patient recruitment and methods of clinical conduct through these relationships, to deliver faster, more inclusive, patient-friendly clinical research.”
“AWS helps power the entire clinical development process—from designing effective trials using analytics and ML capabilities, to unlocking virtual trial capabilities, to accelerating the regulatory submission process”, said Dan Sheeran, General Manager, Healthcare and Life Sciences at Amazon Web Services. “We look forward to working with Science 37 to extend the capabilities and scale of the Metasite to help patients and providers globally and enable their continued innovation. AWS will continue to support Science 37 as they work to modernize clinical research with faster trial enrollment, increased patient retention, and more diverse patient populations.”
“This relationship supports the creation of an environment that benefits clinical trial sponsors, patients, and providers alike,” said Troy Bryenton, Chief Technology Officer, Science 37. “AWS will help enable us to build scale, ensure safety and security, build geo-specific datasets, and further our AL/ML strategy while participating in the growing APN.”
About Science 37
Science 37 Holdings, Inc.’s (Nasdaq: SNCE) mission is to accelerate clinical research by enabling universal trial access for patients. Through our Metasite™ we reach an expanded population beyond the traditional site, delivering on our goal of clinical research that works for everyone—with greater patient diversity. Patients gain the flexibility to participate from the comfort of their own homes, at their local community provider, or at a traditional site when needed. Our Metasite is powered by a proprietary technology platform with in-house medical and operational experts that drive uniform study orchestration, enabling greater compliance and high-quality data. To learn more, visit www.science37.com, or email email@example.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the products offered by Science 37 and the markets in which it operates, and Science 37’s anticipated growth and profitability. These forward-looking statements generally are identified by the words “believe,” “can,” “could”, “seek”, “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “might”, “should,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) the ability to maintain the listing of Science 37’s securities on The Nasdaq Stock Market LLC, (ii) volatility in the price of Science 37’s securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Science 37 operates, variations in performance across competitors, changes in laws and regulations affecting Science 37’s business, changes in its capital structure, and general economic and financial market conditions, including fluctuations in currency exchange rates, economic instability, and inflationary conditions (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional opportunities, (iv) the risk that Science 37 may never achieve or sustain profitability, (v) the risk that Science 37 will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all, (vi) failure to realize anticipated cost savings, and (vii) risks related to general economic and financial market conditions. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Science 37’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 6, 2023 and in the other documents filed by Science 37 from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Science 37 assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Science 37 does not give any assurance that Science 37 will achieve its expectations.